We use cookies to customise content for your subscription and for analytics. If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
The U.S. Court of Appeals for the Second Circuit found that reverse payment settlements of patent infringement lawsuits that keep generic drug manufacturers out of the marketplace do not violate federal antitrust laws
The U.S. Federal Trade Commission’s new proposed Hart-Scott-Rodino Act rules will apply only to transfers of pharmaceutical patent rights and are expected to increase the number of filings
